You are here:

alogliptin plus metformin (Vipdomet)

Advice

following an abbreviated submission:

alogliptin plus metformin combination tablet (Vipdomet®) is accepted for restricted use within NHS Scotland.

Indication under review: in the treatment of adult patients aged 18 years and older with type 2 diabetes mellitus:

• as an adjunct to diet and exercise to improve glycaemic control in adult patients, inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of alogliptin and metformin.

• in combination with pioglitazone (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and pioglitazone.

• in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.

SMC restriction: to use in patients for whom this fixed dose combination of alogliptin and metformin is an appropriate choice of therapy and only when the addition of a sulphonylurea to metformin monotherapy is not appropriate.

For patients in whom dual combination therapy with metformin and alogliptin is appropriate it has the potential to reduce the pill burden at no additional cost. 

Alogliptin/metformin is licensed for use in triple combination therapy with pioglitazone or as add-on to insulin. The manufacturer’s submission related only to the use of alogliptin/ metformin in dual therapy, therefore SMC cannot recommend the use of alogliptin/ metformin in triple therapy with either pioglitazone or insulin.
 

Drug Details

Drug Name: alogliptin plus metformin (Vipdomet)
SMC Drug ID: 998/14
Manufacturer: Takeda UK Ltd
Indication: in the treatment of adult patients aged 18 years and older with type 2 diabetes mellitus: as an adjunct to diet and exercise to improve glycaemic control in adult patients, inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of alogliptin and metformin, in combination with pioglitazone (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and pioglitazone, in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.
BNF Category:
Sub Category: 6.1 Drugs used in diabetes
Submission Type: Abbreviated Submission
Status: Restricted
Date Advice Published: 13 October 2014

Back